Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 290

Sort by

Sort Order Select

Journal Articles

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: A multi-center study in China

Ya-nan Ma, Wenzhi CAI, Hongming Zhu, Ying Lu, Xiaofei Yang, Jian-xin Guo, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 7347.

https://doi.org/10.1182/blood-2025-7347

Published: 2025

Journal Articles

KIT mutant/core binding factor (CBF)-negative (CBF-Neg) AML might be an underestimated and distinct subgroup with poor prognosis: A single-center retrospective study

Rui Jiang, Zhibo Zhang, Yizi Liu, Wenqiang Qu, Zhao Zeng, Linlin Wang, Qian Wang, Jia Yin, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 7003.

https://doi.org/10.1182/blood-2025-7003

Published: 2025

Journal Articles

Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma

Jiaqi Li, Shanglong Feng, Ying Zhang, Yuchen Hua, Liqing Kang, Lei Yu, Jia Chen, Xiebin Bao, Ting Xu, Depei Wu, Caixia Li

Blood (2025) 146 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2025-1933

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome-based CMOP±R regimen achieves superior response in treatment-Naïve non-Hodgkin lymphoma: A phase III clinical trial with matching-adjusted indirect comparison

Tao You, Jin Zhou, Yun Wang, Chenwen Wang, Qian Wang, Xiao Ma, Peng Xu, Yuhu Feng, Jun Fang, Miao Zheng, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2025-1924

Published: 2025

Journal Articles

Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study

Changju Qu, Nana Ping, Qian Zhu, Junhong Li, Xiao Zhang, Fan Xia, Rui Zou, Siyun He, Depei Wu, Zhengming Jin

Blood (2025) 146 (Supplement 1): 1912.

https://doi.org/10.1182/blood-2025-1912

Published: 2025

Journal Articles

Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study

Longfei He, Haiwen Huang, Depei Wu, Tao You, Jin Zhou, Yun Wang, Wanying Chen, Chenwen Wang, Qian Cheng, Kaiyu Sheng

Blood (2025) 146 (Supplement 1): 7100.

https://doi.org/10.1182/blood-2025-7100

Published: 2025

Journal Articles

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

Chenwen Wang, Jin Zhou, Tao You, Yun Wang, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 7256.

https://doi.org/10.1182/blood-2025-7256

Published: 2025

Journal Articles

Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Blood (2025) 146 (Supplement 1): 2528.

https://doi.org/10.1182/blood-2025-2528

Published: 2025

Journal Articles

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Blood (2025) 146 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2025-2526

Published: 2025

Journal Articles

Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress

Shenhao Liu, Chongsheng Qian, Haiping Dai, Lan Dai, Yanjun Wu, Zhen Yao, Zheng Li, Wenjie Gong, Aining Sun, Depei Wu, Shengli Xue

Blood (2025) 146 (Supplement 1): 3358.

https://doi.org/10.1182/blood-2025-3358

Published: 2025

Journal Articles

Auto-HSCT combined with blinatumomab as an allo-HSCT-sparing strategy in newly diagnosed B-ALL: Phase II trial results

Zihao Wang, Chongsheng Qian, Zhen Yao, Zheng Li, Wenjie Gong, Haiping Dai, Yanjun Wu, Kai-Wen Tan, Fangtong Liu, Chao-Ling Wan, Depei Wu, Shengli Xue

Blood (2025) 146 (Supplement 1): 3349.

https://doi.org/10.1182/blood-2025-3349

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Yiyan Zhu, Wenzhi CAI, Xueqing Dou, Ying Wang, Xiaofei Yang, Haiping Dai, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 5103.

https://doi.org/10.1182/blood-2025-5103

Published: 2025

Journal Articles

Bgb-11417: A novel BCL2 inhibitor with robust antileukemic activity in T-cell acute lymphoblastic leukemia, alone or with vincristine

Hongfeng Pang, Chao-Ling Wan, Yuan-Hong Huang, Shuaishuai Ge, Chengqiao Qiu, Songbai Liu, Depei Wu, Haiping Dai, Shengli Xue

Blood (2025) 146 (Supplement 1): 6813.

https://doi.org/10.1182/blood-2025-6813

Published: 2025

Journal Articles

TIP-20: A novel FLT3 inhibitor with potent antileukemia activity

Hongfeng Pang, Zhizhi Zhang, Yuan-Hong Huang, Chengqiao Qiu, Depei Wu, Shengli Xue, Songbai Liu

Blood (2025) 146 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2025-6801

Published: 2025

Journal Articles

Liposomal mitoxantrone demonstrates superiority to traditional mitoxantrone in the treatment of AML

Wenqiang Qu, Zhao Zeng, Peng Ke, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 6782.

https://doi.org/10.1182/blood-2025-6782

Published: 2025

Journal Articles

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP

Blood (2025) 146 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2025-6290

Published: 2025

Journal Articles

Targeting B-cell lymphoma surface protein with a novel peptide: Therapeutic potential and clinical implications

Qian Cheng, Ying Shen, Dandan Lin, Qian Wang, Haiwen Huang, Depei Wu

Blood (2025) 146 (Supplement 1): 2550.

https://doi.org/10.1182/blood-2025-2550

Published: 2025

Journal Articles

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Blood (2025) 146 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2025-4812

Published: 2025

Journal Articles

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of Zefamenib combined with chemotherapy or targeted Agents in patients with Acute Myeloid Leukemia

Haiping Dai, Depei Wu, Suning Chen, Yu Wang

Blood (2025) 146 (Supplement 1): 8257.

https://doi.org/10.1182/blood-2025-8257

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: A multi-center study in China

KIT mutant/core binding factor (CBF)-negative (CBF-Neg) AML might be an underestimated and distinct subgroup with poor prognosis: A single-center retrospective study

Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma

Mitoxantrone hydrochloride liposome-based CMOP±R regimen achieves superior response in treatment-Naïve non-Hodgkin lymphoma: A phase III clinical trial with matching-adjusted indirect comparison

Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study

Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress

Auto-HSCT combined with blinatumomab as an allo-HSCT-sparing strategy in newly diagnosed B-ALL: Phase II trial results

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Bgb-11417: A novel BCL2 inhibitor with robust antileukemic activity in T-cell acute lymphoblastic leukemia, alone or with vincristine

TIP-20: A novel FLT3 inhibitor with potent antileukemia activity

Liposomal mitoxantrone demonstrates superiority to traditional mitoxantrone in the treatment of AML

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP

Targeting B-cell lymphoma surface protein with a novel peptide: Therapeutic potential and clinical implications

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of Zefamenib combined with chemotherapy or targeted Agents in patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology